Small,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 15, 2024
Abstract
The
treatment
of
brain
diseases
has
always
been
the
focus
attention.
Due
to
presence
blood‐brain
barrier
(BBB),
most
small
molecule
drugs
are
difficult
reach
brain,
leading
undesirable
therapeutic
outcomes.
Recently,
nanomedicines
that
can
cross
BBB
and
precisely
target
lesion
sites
have
emerged
as
thrilling
tools
enhance
early
diagnosis
treat
various
intractable
disorders.
Extensive
research
shown
reactive
oxygen
species
(ROS)
play
a
crucial
role
in
occurrence
progression
diseases,
including
tumors
neurodegenerative
(NDDs)
such
Alzheimer's
disease,
Parkinson's
stroke,
or
traumatic
injury,
making
ROS
potential
target.
In
this
review,
on
structure
function
well
mechanisms
first
elaborated
through
which
nanomedicine
traverses
it.
Then,
recent
studies
production
summarized
photodynamic
therapy
(PDT),
chemodynamic
(CDT),
sonodynamic
(SDT)
for
treating
tumors,
depletion
NDDs.
This
provides
valuable
guidance
future
design
ROS‐targeted
disease
treatment.
ongoing
challenges
perspectives
developing
nanomedicine‐based
management
also
discussed
outlined.
Nano Letters,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 17, 2025
Atherosclerosis,
resulting
from
chronic
inflammation
of
the
arterial
wall,
serves
as
underlying
cause
multiple
major
cardiovascular
diseases.
Current
anti-inflammatory
therapies
often
exhibit
limited
and
unsatisfactory
efficacy.
To
address
this,
we
have
designed
a
selenium-doped
copper
formate
(Cuf-Se)
nanozyme
for
treatment
atherosclerosis,
which
possesses
superoxide
dismutase
(SOD)
glutathione
peroxidase
(GPx)-like
activities.
The
Cuf-Se
can
efficiently
scavenge
reactive
oxygen
species
(ROS),
inhibit
cellular
senescence,
prevent
formation
foam
cells.
It
acts
on
macrophages
to
reduce
ROS
levels
lipid
oxidation,
thereby
significantly
inhibiting
inflammation-related
processes.
Notably,
while
cell
formation,
also
alleviates
endothelial
cells
senescence.
After
intravenous
administration,
effectively
inhibits
atherosclerosis
in
mice
through
synergistic
effects
antisenescence
antioxidant
properties,
reducing
plaque
area
by
approximately
5-fold.
This
study
provides
an
effective
strategy
atherosclerosis.
Frontiers in Endocrinology,
Journal Year:
2025,
Volume and Issue:
15
Published: Jan. 21, 2025
Nucleotide-binding
oligomerization
domain
1
(NOD1)
is
an
intracellular
pattern
recognition
receptor
that
detects
injury
signals
and
initiates
inflammatory
responses
host
defense.
Furthermore,
NOD1
serves
as
a
metabolic
mediator
by
influencing
the
metabolism
of
various
tissues,
including
adipose
tissue,
liver,
cardiovascular
pancreatic
β
cells,
adrenal
glands,
bones
through
diverse
mechanisms.
It
has
been
discovered
activated
associated
with
pathological
mechanisms
certain
diseases.
This
review
presents
comprehensive
summary
impact
on
tissue-specific
metabolism.
Polymers,
Journal Year:
2025,
Volume and Issue:
17(5), P. 625 - 625
Published: Feb. 26, 2025
Atherosclerosis
(AS)
is
an
important
causative
agent
of
cardiovascular
diseases,
and
the
occurrence
development
AS
accompanied
by
oxidative
stress,
so
antioxidant
therapy
has
become
one
strategies
for
treatment
AS.
This
study
aimed
to
design
construct
apolipoprotein
ApoA1-modified
inorganic-organic
composite
nanosystem
therapy,
in
which
ApoA1
was
modified
onto
carboxylated
CeO2/Mn3O4
covalent
bonding,
resulting
nanocomplex
with
a
structure
similar
that
high-density
lipoprotein.
The
could
effectively
deliver
nanoparticles
plaque
through
specific
recognition
between
macrophage
at
lesion
site.
For
thing,
alleviate
stress
environment
site
highly
efficient
effect
CeO2/Mn3O4,
played
therapeutic
role
another,
it
eliminate
formed
lipid
plaques
maximally
treat
utilizing
cholesterol
efflux
ApoA1.
Frontiers in Physiology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 26, 2025
Atherosclerosis
(AS),
a
prime
causative
factor
in
cardiovascular
disease,
originates
from
endothelial
cell
dysfunction
(ECD).
Comprising
vital
part
of
the
vascular
endothelium,
cells
play
crucial
role
maintaining
homeostasis,
optimizing
redox
balance,
and
regulating
inflammatory
responses.
More
evidence
shows
that
ECD
not
only
serves
as
an
early
harbinger
AS
but
also
exhibits
strong
association
with
disease
progression.
In
recent
years,
treatment
strategies
for
have
been
continuously
evolving,
encompassing
interventions
ranging
lifestyle
modifications
to
traditional
pharmacotherapy
aimed
at
reducing
risk
factors,
which
demonstrated
ability
improve
function.
Additionally,
novel
such
promising
biotherapy
gene
therapy
drawn
attention.
These
methods
enormous
potential
prospects
improving
function
reversing
AS.
However,
it
is
essential
remain
cognizant
current
treatments
still
present
significant
challenges
regarding
therapeutic
efficacy,
long-term
safety,
ethical
issues.
This
article
aims
provide
systematic
review
these
methods,
analyze
mechanisms
efficacy
various
strategies,
goal
offering
insights
guidance
clinical
practice,
further
advancing
prevention
diseases.
Journal of Nanobiotechnology,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: April 23, 2025
Atherosclerosis
is
a
complex
cardiovascular
disease
driven
by
multiple
factors,
including
aging,
inflammation,
oxidative
stress,
and
plaque
rupture.
The
progression
of
this
often
covert,
emphasizing
the
need
for
early
biomarkers
effective
intervention
measures.
In
recent
years,
advancements
in
therapeutic
strategies
have
highlighted
potential
targeting
specific
processes
atherosclerosis,
such
as
localization,
macrophage
activity,
key
enzymes.
Based
on
this,
review
discusses
role
targeted
drugs
treatment
atherosclerosis.
It
also
focuses
their
clinical
efficacy
anti-atherosclerosis
ability
to
provide
more
precise
approaches.
findings
underscore
that
future
research
can
concentrate
exploring
newer
drug
delivery
systems
further
refine
enhance
long-term
dynamic
management
